Blephamide ophthalmic suspension

drug-information.ru

|Blephamide ophthalmic suspension

Drugs search, click the first letter of a drug name:


| A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | 1 | 2 | 3 | 4 | 5 | 6 | 8 | 9  Home

Blephamide


Generic Name: sulfacetamide sodium and prednisolone acetate
Dosage Form: Ophthalmic suspension

Blephamide Description

Blephamide® ophthalmic suspension is a topical anti-inflammatory/anti-infective combination product for ophthalmic use.

Structural Formulas:

Chemical Names:

Sulfacetamide sodium: N-sulfanilylacetamide monosodium salt monohydrate.

Prednisolone acetate: 11ß, 17, 21-trihydroxypregna-1, 4-diene-3, 20-dione 21-acetate.

Contains:

Actives: sulfacetamide sodium 10%, prednisolone acetate (microfine suspension) 0.2%.

Preservative: benzalkonium chloride (0.004%). Inactives: edetate disodium; polysorbate 80; polyvinyl alcohol 1.4%; potassium phosphate, monobasic; purified water; sodium phosphate, dibasic; sodium thiosulfate; hydrochloric acid and/or sodium hydroxide to adjust the pH (6.6 to 7.2).

Blephamide - Clinical Pharmacology

Corticosteroids suppress the inflammatory response to a variety of agents and they probably delay or slow healing. Since corticosteroids may inhibit the body"s defense mechanism against infection, a concomitant antibacterial drug may be used when this inhibition is considered to be clinically significant in a particular case.

When a decision to administer both a corticosteroid and an antibacterial is made, the administration of such drugs in combination has the advantage of greater patient compliance and convenience, with the added assurance that the appropriate dosage of both drugs is administered. When both types of drugs are in the same formulation, compatibility of ingredients is assured and the correct volume of drug is delivered and retained. The relative potency of corticosteroids depends on the molecular structure, concentration and release from the vehicle.

Microbiology: Sulfacetamide sodium exerts a bacteriostatic effect against susceptible bacteria by restricting the synthesis of folic acid required for growth through competition with p-aminobenzoic acid.

Some strains of these bacteria may be resistant to sulfacetamide or resistant strains may emerge in vivo.

The anti-infective component in these products is included to provide action against specific organisms susceptible to it. Sulfacetamide sodium is active in vitro against susceptible strains of the following microorganisms: Escherichia coli, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus (viridans group), Haemophilus influenzae, Klebsiella species, and Enterobacter species. This product does not provide adequate coverage against: Neisseria species, Pseudomonas species, and Serratia marcescens (see INDICATIONS AND USAGE).

Indications and Usage for Blephamide

A steroid/anti-infective combination is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists.

Ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns or penetration of foreign bodies.

The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye.

The particular antibacterial drug in this product is active against the following common bacterial eye pathogens: Escherichia coli, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus (viridans group), Haemophilus influenzae, Klebsiella species, and Enterobacter species. This product does not provide adequate coverage against: Neisseria species, Pseudomonas species, Serratia marcescens.

A significant percentage of staphylococcal isolates are completely resistant to sulfa drugs.

Contraindications

Blephamide® ophthalmic suspension is contraindicated in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures.

This product is also contraindicated in individuals with known or suspected hypersensitivity to any of the ingredients of this preparation, to other sulfonamides and to other corticosteroids. See WARNINGS. (Hypersensitivity to the antimicrobial component occurs at a higher rate than for other components.)

Warnings

NOT FOR INJECTION INTO THE EYE.

Prolonged use of corticosteroids may result in ocular hypertension/glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision, and in posterior subcapsular cataract formation.

Acute anterior uveitis may occur in susceptible individuals, primarily Blacks.

Prolonged use of Blephamide® ophthalmic suspension may suppress the host response and thus increase the hazard of secondary ocular infections. In those diseases causing thinning of the cornea or sclera, perforation has been known to occur with the use of topical corticosteroids. In acute purulent conditions of the eye, corticosteroids may mask infection or enhance existing infection.

If the product is used for 10 days or longer, intraocular pressure should be routinely monitored even though it may be difficult in children and uncooperative patients. Corticosteroids should be used with caution in the presence of glaucoma. Intraocular pressure should be checked frequently.

A significant percentage of staphylococcal isolates are completely resistant to sulfonamides.

The use of steroids after cataract surgery may delay healing and increase the incidence of filtering blebs.

The use of ocular corticosteroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex). Employment of corticosteroid medication in the treatment of herpes simplex requires great caution.

Topical steroids are not effective in mustard gas keratitis and Sjögren"s keratoconjunctivitis.

Fatalities have occurred, although rarely, due to severe reactions to sulfonamides including Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia and other blood dyscrasias. Sensitization may recur when a sulfonamide is readministered, irrespective of the route of administration.

If signs of hypersensitivity or other serious reactions occur, discontinue use of this preparation. Cross-sensitivity among corticosteroids has been demonstrated (see ADVERSE REACTIONS).

Precautions

General:

The initial prescription and renewal of the medication order beyond 20 milliliters of the suspension should be made by a physician only after examination of the patient with the aid of magnification, such as slit lamp biomicroscopy and, where appropriate, fluorescein staining. If signs and symptoms fail to improve after two days, the patient should be re-evaluated.

The possibility of fungal infections of the cornea should be considered after prolonged corticosteroid dosing. Use with caution in patients with severe dry eye. Fungal cultures should be taken when appropriate.

The p-aminobenzoic acid present in purulent exudates competes with sulfonamides and can reduce their effectiveness.

Information for Patients:

If inflammation or pain persists longer than 48 hours or becomes aggravated, the patient should be advised to discontinue use of the medication and consult a physician (see WARNINGS).

Contact lenses should not be worn during the use of this product.

This product is sterile when packaged. To prevent contamination, care should be taken to avoid touching the applicator tip to eyelids or to any other surface. The use of this bottle by more than one person may spread infection. Keep bottle tightly closed when not in use. Protect from light. Sulfonamide solutions darken on prolonged standing and exposure to heat and light. Do not use if solution has darkened. Yellowing does not affect activity. Keep out of the reach of children.

Laboratory Tests:

Eyelid cultures and tests to determine the susceptibility of organisms to sulfacetamide may be indicated if signs and symptoms persist or recur in spite of the recommended course of treatment with Blephamide® ophthalmic suspension.

Drug Interactions:

Blephamide® ophthalmic suspension is incompatible with silver preparations. Local anesthetics related to p-aminobenzoic acid may antagonize the action of the sulfonamides.

Carcinogenesis, Mutagenesis, Impairment of Fertility:

Prednisolone has been reported to be noncarcinogenic. Long-term animal studies for carcinogenic potential have not been performed with sulfacetamide.

One author detected chromosomal nondisjunction in the yeast Saccharomyces cerevisiae following application of sulfacetamide sodium. The significance of this finding to topical ophthalmic use of sulfacetamide sodium in the human is unknown.

Mutagenic studies with prednisolone have been negative. Studies on reproduction and fertility have not been performed with sulfacetamide. A long-term chronic toxicity study in dogs showed that high oral doses of prednisolone prevented estrus. A decrease in fertility was seen in male and female rats that were mated following oral dosing with another glucocorticosteroid.

Pregnancy:

Teratogenic Effects: Pregnancy Category C. Animal reproduction studies have not been conducted with sulfacetamide sodium. Prednisolone has been shown to be teratogenic in rabbits, hamsters, and mice. In mice, prednisolone has been shown to be teratogenic when given in doses 1 to 10 times the human ocular dose. Dexamethasone, hydrocortisone and prednisolone were ocularly applied to both eyes of pregnant mice five times per day on days 10 through 13 of gestation. A significant increase in the incidence of cleft palate was observed in the fetuses of the treated mice. There are no adequate well-controlled studies in pregnant women dosed with corticosteroids.

Kernicterus may be precipitated in infants by sulfonamides being given systemically during the third trimester of pregnancy. It is not known whether sulfacetamide sodium can cause fetal harm when administered to a pregnant woman or whether it can affect reproductive capacity.

Blephamide® ophthalmic suspension should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nursing Mothers:

It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. Systemically administered sulfonamides are capable of producing kernicterus in infants of lactating women. Because of the potential for serious adverse reactions in nursing infants from sulfacetamide sodium and prednisolone acetate ophthalmic suspensions, a decision should be made whether to discontinue nursing or to discontinue the medication.

Pediatric Use:

Safety and effectiveness in pediatric patients below the age of six have not been established.

Adverse Reactions

Adverse reactions have occurred with corticosteroid/antibacterial combination drugs which can be attributed to the corticosteroid component, the antibacterial component, or the combination. Exact incidence figures are not available since no denominator of treated patients is available.

Reactions occurring most often from the presence of the antibacterial ingredient are allergic sensitizations. Fatalities have occurred, although rarely, due to severe reactions to sulfonamides including Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia, and other blood dyscrasias (See WARNINGS).

Sulfacetamide sodium may cause local irritation.

The reactions due to the corticosteroid component in decreasing order of frequency are: elevation of intraocular pressure (IOP) with possible development of glaucoma and infrequent optic nerve damage, posterior subcapsular cataract formation, and delayed wound healing.

Although systemic effects are extremely uncommon, there have been rare occurrences of systemic hypercorticoidism after use of topical corticosteroids.

Corticosteroid-containing preparations can also cause acute anterior uveitis or perforation of the globe. Mydriasis, loss of accommodation and ptosis have occasionally been reported following local use of corticosteroids.

Secondary Infection: The development of secondary infection has occurred after use of combinations containing corticosteroids and antibacterials. Fungal and viral infections of the cornea are particularly prone to develop coincidentally with long-term applications of corticosteroid. The possibility of fungal invasion must be considered in any persistent corneal ulceration where corticosteroid treatment has been used.

Secondary bacterial ocular infection following suppression of host responses also occurs.

Blephamide Dosage and Administration

SHAKE WELL BEFORE USING. Two drops should be instilled into the conjunctival sac every four hours during the day and at bedtime.

Not more than 20 milliliters should be prescribed initially, and the prescription should not be refilled without further evaluation as outlined in PRECAUTIONS above.

Blephamide® dosage may be reduced, but care should be taken not to discontinue therapy prematurely. In chronic conditions, withdrawal of treatment should be carried out by gradually decreasing the frequency of application.

If signs and symptoms fail to improve after two days, the patient should be re-evaluated (see PRECAUTIONS).

How is Blephamide Supplied

Blephamide® (sulfacetamide sodium–prednisolone acetate ophthalmic suspension, USP) is supplied sterile in opaque white LDPE plastic bottles and white dropper tips with high impact polystyrene (HIPS) caps as follows:

 
5 mL in 10 mL bottle — NDC 11980-022-05
 
10 mL in 15 mL bottle — NDC 11980-022-10

Note: Protect from freezing. Shake well before using.

Storage: Store at 8°-24°C (46°-75°F) in an upright position.

PROTECT FROM LIGHT.

Sulfonamide solutions darken on prolonged standing and exposure to heat and light. Do not use if solution has darkened. Yellowing does not affect activity.

KEEP OUT OF REACH OF CHILDREN.

Rx only

Rev June 2004

© 2004 Allergan, Inc.
Irvine, CA 92612, U.S.A.
® marks owned by Allergan, Inc.
6580X
71735US10P


Blephamide (sulfacetamide sodium and prednisolone acetate)
PRODUCT INFO
Product Code 11980-022 Dosage Form SUSPENSION
Route Of Administration OPHTHALMIC DEA Schedule
INGREDIENTS
Name (Active Moiety) Type Strength
sulfacetamide sodium (sulfacetamide) Active 100 MILLIGRAM  In 1 MILLILITER
prednisolone acetate (prednisolone) Active 2 MILLIGRAM  In 1 MILLILITER
edetate disodium Inactive  
polysorbate 80 Inactive  
polyvinyl alcohol Inactive  
potassium phosphate, monobasic Inactive  
water Inactive  
sodium phosphate, dibasic Inactive  
sodium thiosulfate Inactive  
benzalkonium chloride Inactive  
hydrochloric acid Inactive  
sodium hydroxide. Inactive  
IMPRINT INFORMATION
Characteristic Appearance Characteristic Appearance
Color Score
Shape Symbol
Imprint Code Coating
Size
PACKAGING
# NDC Package Description Multilevel Packaging
1 11980-022-05 5 MILLILITER In 1 BOTTLE, DROPPER None
2 11980-022-10 10 MILLILITER In 1 BOTTLE, DROPPER None

Revised: 03/2007





Where can I get more information about Blephamide ophthalmic suspension ? We recommend to use www.Drugs.com

Typical mistypes for Blephamide ophthalmic suspension
vlephamide ophthalmic suspension, nlephamide ophthalmic suspension, hlephamide ophthalmic suspension, glephamide ophthalmic suspension, bkephamide ophthalmic suspension, bpephamide ophthalmic suspension, boephamide ophthalmic suspension, blwphamide ophthalmic suspension, blsphamide ophthalmic suspension, bldphamide ophthalmic suspension, blrphamide ophthalmic suspension, bl4phamide ophthalmic suspension, bl3phamide ophthalmic suspension, bleohamide ophthalmic suspension, blelhamide ophthalmic suspension, ble-hamide ophthalmic suspension, ble0hamide ophthalmic suspension, blepgamide ophthalmic suspension, blepbamide ophthalmic suspension, blepnamide ophthalmic suspension, blepjamide ophthalmic suspension, blepuamide ophthalmic suspension, blepyamide ophthalmic suspension, blephzmide ophthalmic suspension, blephsmide ophthalmic suspension, blephwmide ophthalmic suspension, blephqmide ophthalmic suspension, blephanide ophthalmic suspension, blephakide ophthalmic suspension, blephajide ophthalmic suspension, blephamude ophthalmic suspension, blephamjde ophthalmic suspension, blephamkde ophthalmic suspension, blephamode ophthalmic suspension, blepham9de ophthalmic suspension, blepham8de ophthalmic suspension, blephamise ophthalmic suspension, blephamixe ophthalmic suspension, blephamice ophthalmic suspension, blephamife ophthalmic suspension, blephamire ophthalmic suspension, blephamiee ophthalmic suspension, blephamidw ophthalmic suspension, blephamids ophthalmic suspension, blephamidd ophthalmic suspension, blephamidr ophthalmic suspension, blephamid4 ophthalmic suspension, blephamid3 ophthalmic suspension, blephamide iphthalmic suspension, blephamide kphthalmic suspension, blephamide lphthalmic suspension, blephamide pphthalmic suspension, blephamide 0phthalmic suspension, blephamide 9phthalmic suspension, blephamide oohthalmic suspension, blephamide olhthalmic suspension, blephamide o-hthalmic suspension, blephamide o0hthalmic suspension, blephamide opgthalmic suspension, blephamide opbthalmic suspension, blephamide opnthalmic suspension, blephamide opjthalmic suspension, blephamide oputhalmic suspension, blephamide opythalmic suspension, blephamide ophrhalmic suspension, blephamide ophfhalmic suspension, blephamide ophghalmic suspension, blephamide ophyhalmic suspension, blephamide oph6halmic suspension, blephamide oph5halmic suspension, blephamide ophtgalmic suspension, blephamide ophtbalmic suspension, blephamide ophtnalmic suspension, blephamide ophtjalmic suspension, blephamide ophtualmic suspension, blephamide ophtyalmic suspension, blephamide ophthzlmic suspension, blephamide ophthslmic suspension, blephamide ophthwlmic suspension, blephamide ophthqlmic suspension, blephamide ophthakmic suspension, blephamide ophthapmic suspension, blephamide ophthaomic suspension, blephamide ophthalnic suspension, blephamide ophthalkic suspension, blephamide ophthaljic suspension, blephamide ophthalmuc suspension, blephamide ophthalmjc suspension, blephamide ophthalmkc suspension, blephamide ophthalmoc suspension, blephamide ophthalm9c suspension, blephamide ophthalm8c suspension, blephamide ophthalmix suspension, blephamide ophthalmiv suspension, blephamide ophthalmif suspension, blephamide ophthalmid suspension, blephamide ophthalmic auspension, blephamide ophthalmic zuspension, blephamide ophthalmic xuspension, blephamide ophthalmic duspension, blephamide ophthalmic euspension, blephamide ophthalmic wuspension, blephamide ophthalmic syspension, blephamide ophthalmic shspension, blephamide ophthalmic sjspension, blephamide ophthalmic sispension, blephamide ophthalmic s8spension, blephamide ophthalmic s7spension, blephamide ophthalmic suapension, blephamide ophthalmic suzpension, blephamide ophthalmic suxpension, blephamide ophthalmic sudpension, blephamide ophthalmic suepension, blephamide ophthalmic suwpension, blephamide ophthalmic susoension, blephamide ophthalmic suslension, blephamide ophthalmic sus-ension, blephamide ophthalmic sus0ension, blephamide ophthalmic suspwnsion, blephamide ophthalmic suspsnsion, blephamide ophthalmic suspdnsion, blephamide ophthalmic susprnsion, blephamide ophthalmic susp4nsion, blephamide ophthalmic susp3nsion, blephamide ophthalmic suspebsion, blephamide ophthalmic suspemsion, blephamide ophthalmic suspejsion, blephamide ophthalmic suspehsion, blephamide ophthalmic suspenaion, blephamide ophthalmic suspenzion, blephamide ophthalmic suspenxion, blephamide ophthalmic suspendion, blephamide ophthalmic suspeneion, blephamide ophthalmic suspenwion, blephamide ophthalmic suspensuon, blephamide ophthalmic suspensjon, blephamide ophthalmic suspenskon, blephamide ophthalmic suspensoon, blephamide ophthalmic suspens9on, blephamide ophthalmic suspens8on, blephamide ophthalmic suspensiin, blephamide ophthalmic suspensikn, blephamide ophthalmic suspensiln, blephamide ophthalmic suspensipn, blephamide ophthalmic suspensi0n, blephamide ophthalmic suspensi9n, blephamide ophthalmic suspensiob, blephamide ophthalmic suspensiom, blephamide ophthalmic suspensioj, blephamide ophthalmic suspensioh, lephamide ophthalmic suspension, bephamide ophthalmic suspension, blphamide ophthalmic suspension, blehamide ophthalmic suspension, blepamide ophthalmic suspension, blephmide ophthalmic suspension, blephaide ophthalmic suspension, blephamde ophthalmic suspension, blephamie ophthalmic suspension, blephamid ophthalmic suspension, blephamideophthalmic suspension, blephamide phthalmic suspension, blephamide ohthalmic suspension, blephamide opthalmic suspension, blephamide ophhalmic suspension, blephamide ophtalmic suspension, blephamide ophthlmic suspension, blephamide ophthamic suspension, blephamide ophthalic suspension, blephamide ophthalmc suspension, blephamide ophthalmi suspension, blephamide ophthalmicsuspension, blephamide ophthalmic uspension, blephamide ophthalmic sspension, blephamide ophthalmic supension, blephamide ophthalmic susension, blephamide ophthalmic suspnsion, blephamide ophthalmic suspesion, blephamide ophthalmic suspenion, blephamide ophthalmic suspenson, blephamide ophthalmic suspensin, blephamide ophthalmic suspensio, lbephamide ophthalmic suspension, belphamide ophthalmic suspension, blpehamide ophthalmic suspension, blehpamide ophthalmic suspension, blepahmide ophthalmic suspension, blephmaide ophthalmic suspension, blephaimde ophthalmic suspension, blephamdie ophthalmic suspension, blephamied ophthalmic suspension, blephamid eophthalmic suspension, blephamideo phthalmic suspension, blephamide pohthalmic suspension, blephamide ohpthalmic suspension, blephamide opthhalmic suspension, blephamide ophhtalmic suspension, blephamide ophtahlmic suspension, blephamide ophthlamic suspension, blephamide ophthamlic suspension, blephamide ophthalimc suspension, blephamide ophthalmci suspension, blephamide ophthalmi csuspension, blephamide ophthalmics uspension, blephamide ophthalmic usspension, blephamide ophthalmic ssupension, blephamide ophthalmic supsension, blephamide ophthalmic susepnsion, blephamide ophthalmic suspnesion, blephamide ophthalmic suspesnion, blephamide ophthalmic suspenison, blephamide ophthalmic suspensoin, blephamide ophthalmic suspensino, bblephamide ophthalmic suspension, bllephamide ophthalmic suspension, bleephamide ophthalmic suspension, blepphamide ophthalmic suspension, blephhamide ophthalmic suspension, blephaamide ophthalmic suspension, blephammide ophthalmic suspension, blephamiide ophthalmic suspension, blephamidde ophthalmic suspension, blephamidee ophthalmic suspension, blephamide ophthalmic suspension, blephamide oophthalmic suspension, blephamide opphthalmic suspension, blephamide ophhthalmic suspension, blephamide ophtthalmic suspension, blephamide ophthhalmic suspension, blephamide ophthaalmic suspension, blephamide ophthallmic suspension, blephamide ophthalmmic suspension, blephamide ophthalmiic suspension, blephamide ophthalmicc suspension, blephamide ophthalmic suspension, blephamide ophthalmic ssuspension, blephamide ophthalmic suuspension, blephamide ophthalmic susspension, blephamide ophthalmic susppension, blephamide ophthalmic suspeension, blephamide ophthalmic suspennsion, blephamide ophthalmic suspenssion, blephamide ophthalmic suspensiion, blephamide ophthalmic suspensioon, blephamide ophthalmic suspensionn, etc.



© Copyright by drug-information.ru 2001-2019. All rights reserved